MEAI: What To Know About This Synthetic Psychedelic
Hint: It Can Help You Lose Weight And Fight Addictions
Despite the thousands of pharmaceutical medications, psychedelic drugs, and plant-based therapeutics available in the world today, there is still a serious need for more innovative medications.
New breakthrough drugs are still needed to treat a wide range of untreatable conditions, especially those that are psychological in nature, such as addictions and unhealthy relationships with food – which then drive obesity. When left untreated, these lifestyles can cause chronic and even fatal illnesses. Whether it’s for treating old diseases, rare conditions, and even the rise of new disease that continue to afflict it, we need more new medications.
And over the last few years, MEAI is one of the most exciting drugs out there. MEAI, which is a 5-methoxy – 2-aminoindane compound, is a non-hallucinogenic, synthetic psychedelic’ has been shown to possess the potential of becoming an incredible therapeutic drug for hard-to-treat conditions including alcoholism. It was created by the Chief Scientific Officer of Clearmind Medicine, a biotech firm focused on developing psychedelic-based drugs that are aimed at solving common health issues such as alcohol use disorder, addiction, and obesity. However, their flagship treatment is focused on alcohol use disorder since it’s so common, as well as obesity.
They already currently have 15 patients and are working on more.
Last March 2024, Clearmind, with offices in Vancouver as well as in Israel, announced that they received the green light from the Israely Ministry of Health to start phase I/IIa clinical trials for their proprietary MEAI-based capsule called CMND-100 for treating alcohol use disorder (AUD).
More recently in July, Clearmind Medicine was given FDA approval to conduct further studies in the United States. “Our dedicated team has been relentlessly focused on creating an innovative solution to the global alcohol abuse crisis. We are keen to continue our efforts to assist those desperately in need,” said Dr. Adi Zuloff-Shani, Clearmind’s CEO. “We believe our non-hallucinogenic, psychedelic treatment could address the global demand for effective addiction therapies,” she said.
Based on their discovery and studies of MEAI, Clearmind Medicine is well-positioned to be a major trailblazer in the world of science and medicine.
MEAI’s Success In Treating Addiction
Alcoholism or alcohol use disorder has proven to be extremely difficult to treat. There are several factors that make it challenging to address, primarily the biological nature of the disease. Since excessive alcohol consumption changes the brain chemistry, especially areas that are related to pleasure and reward, the brain then becomes even more dependent on alcohol to make one feel good over time. There is also a physical dependence that grows.
There is also a psychological factor involved: it has become normal for people to turn to alcohol to deal with stress. And when individuals quit, it’ common for people to have strong cravings of alcohol especially when they are triggered by social situations or environments.
According to the article, MEAI has shown to be effective in curbing the craving for drinking alcoholic drinks, while providing the consumer with a euphoric experience. It does that by interacting with the serotonergic system, which is known to play an important role in regulating alcohol dependence and intake. In addition, they found that MEAI interacts with other receptors including those for serotonin, dopamine, and norepinephrine, which also help to curb drinking behavior.
According to Professor Mark Haden, MEAI also has the potential to treat cocaine addictions.
MEAI For Weight Loss
Earlier this month, Clearmind also published the findings of their study on weight loss. The results were promising: they found that MEAI, when administered to animal subjects, was found to be effective in decreasing obesity by reducing fat mass. That said, it was successful in maintaining lean mass.
Additionally, MEAI showed an incredible ability to improve metabolism and glycemic control, all while reducing glucose intolerance, hyperglycemia, and hyperinsulinemia. MEAI also mitigated fatty liver, improved energy levels, and boosted energy expenditures. “The newly published paper shows the efficacy of MEAI as a promising therapeutic approach for weight loss and normalization of metabolic disorders,” said Dr. Zuloff-Shani. “The comprehensive experiments demonstrate the ability of MEAI to significantly reduce weight by lowering the fat mass, improve the body’s metabolic function and lower fat accumulation in the liver, all of which position this treatment as potential breakthrough in the treatment of obesity. We are excited by the potential of MEAI, which may position it at the forefront of weight loss treatments, even compared to the marketed treatments in the percentage of weight loss, its unique mechanism of action, the easy administration and in the fact that no food consumption constraints are required” she said.
Clearmind Given Patent For MEAI
Just on August 22nd, Clearmind announced that they were granted a new patent approval from the United States Patent and Trademark Office (USPTO) for the MEAI-based binge behavior program.
“We are proud to continue leading the way in IP protection within this space,” said Dr. Zuloff-Shani. “Expanding and maintaining our patent portfolio, particularly in the US, remains a key objective for us. We believe that we hold one of the largest portfolios in the market, covering our core areas: MEAI, binge behavior, addictions, mental disorders, as well as new psychedelic compounds and combinations identified and researched by our team,” she said.
Conclusion
Given the high success rate of their studies, we can anticipate even more exciting results and findings from Clearmind Medicine. Because of MEAI, we may be able to look forward to treating obesity and addiction more effectively in the near future.
SYNTHETIC MARIJUANA IS NOT EVEN MARIJUANA, READ ON...
